


Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2



* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEx enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 43 Jun 06 PASCAL enhanced with additional data
NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:02:42 ON 30 JUN 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:02:53 ON 30 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

DICTIONARY FILE UPDATES: 29 JUN 2003 HIGHEST RN 539790-82-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10016280.1

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1	STR
----	-----



G1 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S 11

SAMPLE SEARCH INITIATED 13:03:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 92 TO ITERATE

100.0% PROCESSED 92 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH ** COMPLETE**

PROJECTED ITERATIONS: 1265 TO 2415

PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

```
=> s ll sss full
```

FULL SEARCH INITIATED 13:03:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1825 TO ITERATE

100.0% PROCESSED 1825 ITERATIONS

176 ANSWERS

SEARCH TIME: 00.00.01

L3 176 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

Patel

<6/302003>

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 13:03:38 ON 30 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jun 2003 VOL 139 ISS 1

FILE LAST UPDATED: 29 Jun 2003 (20030629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 7 L3

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:487536 CAPLUS

DN 137:63250

TI Quinazoline derivatives as inhibitors of human EFG tyrosine kinase

IN Himmelsbach, Frank; Langkopf, Elke; Blech, Stefan; Jung, Birgit; Baum, Elke; Solca, Flavio

PA Boehringer Ingelheim Pharma Kg, Germany

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050043	A1	20020627	WO 2001-EP14569	20011212
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10063435	A1	20020704	DE 2000-10063435A	20001220
	AU 2002019174	A5	20020701	DE 2000-10063435	20001220
				AU 2002-19174	20011212
				DE 2000-10063435A	20001220

US 2002173509

A1 20021121

WO 2001-EP14569W 20011212

US 2001-23099 20011217

DE 2000-10063435A 20001220

US 2000-259201PP 20001228

OS MARPAT 137:63250

IT 439081-40-0P 439081-48-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of quinazoline derivs. as inhibitors of human EFG tyrosine
kinase)

RN 439081-40-0 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(2S)-tetrahydro-2-
furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 439081-48-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
6-quinazolinyl]-4-[(2-methoxyethyl)methylamino]- (9CI) (CA INDEX NAME)



IT 439081-20-6P 439081-21-7P 439081-22-8P
439081-24-0P 439081-25-1P 439081-27-3P
439081-28-4P 439081-31-9P 439081-32-0P
439081-36-4P 439081-37-5P 439081-38-6P

439081-39-7P 439081-45-5P 439081-46-6P


439081-47-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazoline derivs. as inhibitors of human EFG tyrosine kinase)


RN 439081-20-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-21-7 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 439081-22-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)




RN 439081-24-0 CAPLUS

CN 2-Butenamide, 4-[[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-9CI] (CA INDEX NAME)



RN 439081-25-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(4-morpholinyl)-9CI] (CA INDEX NAME)




RN 439081-27-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(2R)-tetrahydro-2-furanyl]methyl]amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-28-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(2S)-tetrahydro-2-furanyl]methyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-31-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(cyclopropylmethylamino)- (9CI) (CA INDEX NAME)




RN 439081-32-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(tetrahydro-2H-pyran-4-yl)methyl]amino]-(9CI)
(CA INDEX NAME)




RN 439081-36-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-(dimethylamino)-(9CI) (CA INDEX NAME)




RN 439081-37-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 439081-38-6 CAPLUS


CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 439081-39-7 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(2R)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 439081-45-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2-(2-ethoxymethyl-2H-tetrahydrofuran-2-ylidene)oxy]-6-quinazolinyl]-4-(ethylmethlamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439081-46-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[2-(2-ethoxymethyl-2H-tetrahydrofuran-2-ylidene)oxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.





RN 439081-47-7 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[[(2S)-tetrahydro-2-furanyl]methoxy]-6-quinazolinyl]-4-[methyl(1-methylethyl)amino]-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



GI



AB Quinazoline derivs. I [R = PhCH₂, PhCHMe, 3,4-Cl(F)C₆H₃; R₁ = NMe₂, NEt₂, NEtCH₂CH₂OMe, N(CH₂CH₂OMe)₂, morpholino; R₂ = Me, Et, CHMe₂, cyclopropyl, CH₂CH₂OMe, 3-tetrahydrofuryl, 2-tetrahydrofurylmethyl, 3-tetrahydrofurylmethyl, 4-tetrahydropyranyl, 4-tetrahydropyranylmethyl; R₃ = cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, 3-tetrahydrofuranyloxy, 2-tetrahydrofuranylmethoxy, 3-tetrahydrofuranylmethoxy, 4-tetrahydropyranyloxy, 4-tetrahydropyranylmethoxy] were prepd. for use as inhibitors of signal transduction caused by human EFG receptor tyrosine kinase. They are useful in the treatment of tumoral diseases, diseases of the lung and the respiratory tract, the gastrointestinal tract, and the gallbladder and bile ducts. Thus, the quinazoline II was prepd. by converting bromocrotonic acid to its chloride, and reaction with 4-[(3-chloro-4-fluorophenyl)amino]-6-amino-7-cyclopropylmethoxyquinazoline, followed by MeNHCH₂CH₂OMe. II had an IC₅₀ against human EFG receptor kinase of 0.7 nM.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:171892 CAPLUS

DN 136:216762

TI Preparation of 4-amino-6-heterocyclylcarbonylaminoquinazolines as epidermal growth factor receptor signal transduction inhibitors

IN Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PA Boehringer Ingelheim Pharma Kg, Germany

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018376	A1	20020307	WO 2001-EP9536	20010818
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10042062 A1 20020307 DE 2000-10042062A 20000826
 AU 2001095482 A5 20020313 DE 2000-10042062 20000826
 AU 2001-95482 20010818
 DE 2000-10042062A 20000826
 WO 2001-EP9536 W 20010818
 EP 2001-976108 20010818
 EP 1315720 A1 20030604
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 DE 2000-10042062A 20000826
 WO 2001-EP9536 W 20010818
 US 2001-934631 20010822
 DE 2000-10042062A 20000826
 US 2000-230542PP 20000905

OS MARPAT 136:216762

IT 402569-98-6P 402569-99-7P 402570-00-7P
 402570-01-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of (amino)(heterocyclylcarbonylamino)quinazolines as epidermal
 growth factor receptor signal transduction inhibitors)

RN 402569-98-6 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-[(2R)-2-(methoxymethyl)-6-oxo-4-morpholinyl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 402569-99-7 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-(2-oxo-1,9-dioxo-4-azaspiro[5.5]undec-4-yl)- (9CI) (CA
 INDEX NAME)



RN 402570-00-7 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-(methoxymethyl)-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402570-01-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[2-(2-methoxyethyl)-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)



IT 402569-87-3P 402569-89-5P 402569-90-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (amino)(heterocyclylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402569-87-3 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxy-3-methoxypropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 402569-89-5 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

AB Title compds. [I; X = N, (substituted) methynyl; R1 = H, Me; R2 = (substituted) Ph, PhCH2, 1-phenylethyl; R3 = H, Me; A = (substituted) vinyl, ethynyl, 1,3-butadien-1,4-yl; B = (substituted) alkenyl, alkenylcarbonyl, etc.; C = (substituted) 2-oxomorpholin-4-yl, etc; D = oxyalkenyl, O; E = (substituted) amino, alkenylimino, imidazolyl, cycloalkyl; or DE = H, (substituted) alkoxy, etc.], were prepd. Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(ethoxycarbonylmethyl)-N-((R)-2-hydroxy-3-methoxypropyl)amino]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline (prepn. given) and MeSO2OH in MeCN were stirred for 4 h under reflux to give 69% 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[(R)-2-methoxymethyl-6-oxomorpholin-4-yl]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline. The latter inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC50 = .2 nM. The invention relates to the use of the title compds. for treating tumor diseases, and lung and respiratory tract disorders.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:171889 CAPLUS

DN 136:232315

TI Preparation of 4-amino-6-vinylcarbonylaminoquinazolines as epidermal growth factor receptor signal transduction inhibitors

IN Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PA Boehringer Ingelheim Pharma Kg, Germany

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018373	A1	20020307	WO 2001-EP9537	20010818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10042060	A1	20020307	DE 2000-10042060A	20000826
	US 2002077330	A1	20020620	DE 2000-10042060	20000826
				US 2001-929931	20010815
				DE 2000-10042060A	20000826
				US 2000-230389PP	20000906
	AU 2001084021	A5	20020313	AU 2001-84021	20010818
				DE 2000-10042060A	20000826
	EP 1315717	A1	20030604	WO 2001-EP9537 W	20010818
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		EP 2001-962953	20010818
				DE 2000-10042060A	20000826
				WO 2001-EP9537 W	20010818

OS MARPAT 136:232315


IT 402855-15-6P 402855-53-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of (amino)(vinylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402855-15-6 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-53-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 402855-16-7P 402855-17-8P 402855-18-9P
 402855-19-0P 402855-33-8P 402855-35-0P
 402855-46-3P 402855-47-4P 402855-48-5P
 402855-49-6P 402855-51-0P 402855-52-1P
 402855-54-3P 402855-70-3P 402855-71-4P
 402855-73-6P 402855-74-7P 402855-75-8P
 402855-76-9P 402855-77-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (amino)(vinylcarbonylamino)quinazolines as epidermal growth factor receptor signal transduction inhibitors)

RN 402855-16-7 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 402855-17-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(1,3-dioxolan-2-ylmethyl)methylamino]- (9CI) (CA INDEX NAME)






RN 402855-18-9 CAPLUS

CN L-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 402855-19-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 402855-33-8 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 402855-35-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5-ethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)






RN 402855-46-3 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-47-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(2,2-dimethyl-6-oxo-4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 402855-48-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 402855-49-6 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 402855-51-0 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2S)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-52-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-54-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(3S)-3-methyl-2-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-70-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-3-furanyl)methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-71-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-73-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)methoxy]-6-quinazolinyl]-4-[(2S)-2-methyl-6-oxo-4-morpholinyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 402855-74-7 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 402855-75-8 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-2-methylpropyl)- (9CI)
(CA INDEX NAME)



RN 402855-76-9 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-1,1-dimethylethyl)-(9CI) (CA INDEX NAME)




RN 402855-77-0 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[(2R)-2-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



GI



I

AB Title compds. [I; R1 = PhCH₂, 1-phenylethyl, (substituted) Ph; R2 = N-[(1,3-dioxolan-2-yl)methyl]methylamino, (substituted) R₄OCOCH₂NCH₂CH₂OH, 2-oxomorpholin-4-yl; R₄ = H, alkyl; R₃ = H, (alkoxy)alkoxy, cycloalkylalkoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy, tetrahydropyranylmethoxy; n = 1-3], were prepd. Thus, a mixt. of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopropylmethoxyquinazoline (prepn. given) and diisopropylethylamine in THF was dropwise treated under ice-cooling with BrCH₂CH:CHCO₂Cl (prepn. given) in CH₂Cl₂ followed by stirring for 1 h under ice-cooling and for 2 h at room temp. and addn. of (S)-(2-hydroxypropylamino)acetic acid tert-Bu ester in CH₂Cl₂ to give after stirring over night at room temp. and stirring for 5 h at 60.degree. 64% 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-[N-(tert-butyloxycarbonylmethyl)-N-((S)-2-hydroxyprop-1-yl)amino]-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline. Several I inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC₅₀ = 0.02-15 nM. The invention relates to the use of the title compds. for treating tumor diseases, and lung and respiratory tract disorders.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2001:762992 CAPLUS

DN 135:303907

TI Preparation of quinazolines as inhibitors of epidermal growth

factor-mediated signal transduction.

IN Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077104	A1	20011018	WO 2001-EP3694	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10017539	A1	20011011	DE 2000-10017539A	20000408
DE 10040525	A1	20020228	DE 2000-10040525A	20000818
EP 1280798	A1	20030205	EP 2001-938076	20010331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			DE 2000-10017539A	20000408
			DE 2000-10040525A	20000818
			WO 2001-EP3694 W	20010331

PATENT FAMILY INFORMATION:

FAN 2001:747043

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10017539	A1	20011011	DE 2000-10017539	20000408
US 2001044435	A1	20011122	US 2001-816003	20010323
			DE 2000-10017539A	20000408
			DE 2000-10040525A	20000818
WO 2001077104	A1	20011018	WO 2001-EP3694	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			DE 2000-10017539A	20000408
			DE 2000-10040525A	20000818
EP 1280798	A1	20030205	EP 2001-938076	20010331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			DE 2000-10017539A	20000408
			DE 2000-10040525A	20000818
			WO 2001-EP3694 W	20010331


OS MARPAT 135:303907

IT 365532-35-0P 365532-36-1P 365532-37-2P
365532-39-4P 365532-40-7P 365532-41-8P
365532-42-9P 365532-44-1P 365532-45-2P
365532-46-3P 365532-47-4P 365532-48-5P
365532-49-6P 367282-07-3P 367282-12-0P
367282-15-3P 367282-23-3P 367282-25-5P
367282-27-7P 367282-29-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)

RN 365532-35-0 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 365532-36-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[[(2R)-tetrahydro-5-oxo-2-furanyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.






RN 365532-37-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 365532-39-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-5-oxo-3-furanyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 365532-40-7 CAPLUS


CN 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-3-[1-(tetrahydro-5-oxo-3-furanyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-41-8 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365532-42-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[2-[(tetrahydro-2-oxo-3-furanyl)thio]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 365532-44-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(3-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)




RN 365532-45-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(hexahydro-3-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-(9CI) (CA INDEX NAME)




RN 365532-46-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)-(9CI) (CA INDEX NAME)




RN 365532-47-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(hexahydro-1-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-(9CI) (CA INDEX NAME)




RN 365532-48-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(tetrahydro-2-oxo-3-furanyl)thio]-1-piperidinyl]-(9CI) (CA INDEX NAME)




RN 365532-49-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2,2-dimethyl-6-oxo-4-morpholinyl)methyl]-1-piperidinyl]-(9CI) (CA INDEX NAME)



RN 367282-07-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl 1-(tetrahydro-2-oxo-3-furanyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 367282-12-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl 1-[(2S)-tetrahydro-5-oxo-2-furanyl]carbonyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


PAGE 1-A



PAGE 1-B


F

RN 367282-15-3 CAPLUS
CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[1-(tetrahydro-2-oxo-3-furanyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)



RN 367282-23-3 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(2-oxo-4-morpholinyl)-1-piperidinyl]-(9CI) (CA INDEX NAME)



RN 367282-25-5 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(2R)-2-methyl-6-oxo-4-morpholinyl]-1-piperidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 367282-27-7 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-methyl-2-oxo-1-oxa-4,9-diazaspiro[5.5]undec-9-yl)-(9CI) (CA INDEX NAME)



RN 367282-29-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-oxo-3-oxa-9-azaspiro[5.5]undec-9-yl)-(9CI) (CA INDEX NAME)




IT 367283-05-4 367283-07-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)

RN 367283-05-4 CAPLUS

CN Glycine, N-[1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]-N-(2-hydroxyethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 367283-07-6 CAPLUS

CN Glycine, N-[1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]-N-[(2R)-2-hydroxypropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 290303-47-8P 290304-01-7P 365532-06-5P

365532-07-6P 365532-18-9P 365532-19-0P


367282-36-8P 367282-44-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of quinazolines as inhibitors of epidermal growth factor-mediated signal transduction)


RN 290303-47-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290304-01-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 365532-06-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(methylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-07-6 CAPLUS


CN 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 365532-18-9 CAPLUS


CN Carbamic acid, [1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-

(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 365532-19-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-3-oxo-1-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 367282-36-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(methyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 367282-44-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]methylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; X = NCN, N; R¹ = H, alkyl; R² = (substituted) Ph, PhCH₂, PhCH₂CH₂; R³ = H, alkyl; R⁴ = H, alkoxy, cycloalkoxy, cycloalkylalkoxy; A = (substituted) vinylene; B = bond, (fluoro)alkylene; D = substituted pyrrolidinyl, piperidinyl, piperazinyl, etc.], were prepd. Thus, 4-[(3-chloro-4-fluorophenyl)amino]-6-[[[4-(piperazin-1-yl)-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline (prepn. given) in THF was

treated with Et3N and then with 3-bromodihydrofuran-2-one in THF under ice cooling followed by stirring for 48 h at room temp. to give 56% 4-[(3-chloro-4-fluorophenyl)amino]-6-[[4-[4-(2-oxotetrahydrofuran-3-yl)piperazin-1-yl]-1-oxo-2-buten-1-yl]amino]-7-cyclopropylmethoxyquinazoline. The latter inhibited epidermal growth factor (EGF)-dependent proliferation of F/L-HERc cells with IC50 = 0.05 nM.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2001:747043 CAPLUS
DN 135:303901
TI Bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction
IN Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Blech, Stefan; Solca, Flavio
PA Boehringer Ingelheim Pharma KG, Germany
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10017539	A1	20011011	DE 2000-10017539	20000408
	US 2001044435	A1	20011122	US 2001-816003	20010323
				DE 2000-10017539A	20000408
				DE 2000-10040525A	20000818
WO	2001077104	A1	20011018	WO 2001-EP3694	20010331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				DE 2000-10017539A	20000408
				DE 2000-10040525A	20000818
EP	1280798	A1	20030205	EP 2001-938076	20010331
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2000-10017539A	20000408
				DE 2000-10040525A	20000818
				WO 2001-EP3694 W	20010331

PATENT FAMILY INFORMATION:

FAN 2001:762992

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077104	A1	20011018	WO 2001-EP3694	20010331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 10017539 A1 20011011 DE 2000-10017539A 20000408
DE 10040525 A1 20020228 DE 2000-10040525A 20000818
EP 1280798 A1 20030205 EP 2001-938076 20010331

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

DE 2000-10017539A 20000408
DE 2000-10040525A 20000818
WO 2001-EP3694 W 20010331


OS MARPAT 135:303901

IT 365532-35-0P 365532-39-4P 365532-42-9P
365532-45-2P 365532-47-4P 365532-48-5P
365532-49-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction)


RN 365532-35-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 365532-39-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-5-oxo-3-furanyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 365532-42-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[2-[(tetrahydro-2-oxo-3-furanyl)thio]ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 365532-45-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(hexahydro-3-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)- (9CI) (CA INDEX NAME)




RN 365532-47-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-(hexahydro-1-oxopyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-(9CI) (CA INDEX NAME)




RN 365532-48-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[4-[(tetrahydro-2-oxo-3-furanyl)thio]-1-piperidiny]- (9CI) (CA INDEX NAME)



RN 365532-49-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[4-[(2,2-dimethyl-6-oxo-4-morpholinyl)methyl]-1-piperidiny]- (9CI) (CA INDEX NAME)




IT 290303-47-8P 290304-01-7P 365532-06-5P
 365532-07-6P 365532-10-1P 365532-18-9P
 365532-19-0P 365532-21-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(prepn. of bicyclic heterocycles as inhibitors of epidermal growth
 factor receptor mediated signal transduction)


RN 290303-47-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-
 6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290304-01-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-
 (cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 365532-06-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(methylamino)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-07-6 CAPLUS


CN 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-3-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 365532-10-1 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-

6-quinazolinyl]-4-[1-(methylamino)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 365532-18-9 CAPLUS

CN Carbamic acid, [1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 365532-19-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-3-oxo-1-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 365532-21-4 CAPLUS

CN Carbamic acid, [4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-1-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 365532-36-1P 365532-37-2P 365532-38-3P

365532-40-7P 365532-41-8P 365532-43-0P

365532-44-1P 365532-46-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of bicyclic heterocycles as inhibitors of epidermal growth factor receptor mediated signal transduction)

RN 365532-36-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[4-[(2R)-tetrahydro-5-oxo-2-furanyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 365532-37-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 365532-38-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[1-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-40-7 CAPLUS


CN 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-3-[1-(tetrahydro-5-oxo-3-furanyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 365532-41-8 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[[2S]-tetrahydro-5-oxo-2-furanyl]carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365532-43-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(tetrahydro-2-oxo-3-furanyl)-1-piperidinyl]- (9CI)
(CA INDEX NAME)




RN 365532-44-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(3-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)





RN 365532-46-3 CAPLUS

CN 2-Butenamide, N'-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-oxo-2-oxa-8-azaspiro[4.5]dec-8-yl)-(9CI) (CA INDEX NAME)




GI




Patel

<6/302003>



I



II

AB Bicyclic heterocycles I [X = N, CCN; R = substituted NH₂; R₁ = H, alkyl; R₂ = acyl; R₃ = H, (un)substituted alkoxy, cycloalkoxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, tetrahydrofuranylmethoxy, tetrahydropyranylmethoxy] were prep'd. for use as inhibitors of tyrosine kinase-mediated signal transduction for treatment of tumors and diseases of the lung and airway. Thus, 4-[(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline was treated with cyclopropylmethanol, followed by redn. to the amine, reaction with 4-bromocrotonic acid and N-tert.-butoxycarbonylpiperazine, and deblocking to give the quinazoline II. II had an IC₅₀ for inhibition of epidermal growth factor dependent proliferation of 0.05 nM.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2000:911231 CAPLUS

DN 134:71599

TI Preparation of aminoquinazolines and aminoquinolines as epidermal growth factor receptor signal transduction inhibitors.

IN Himmelsbach, Frank; Langkopf, Elke; Metz, Thomas; Solca, Flavio; Jung, Birgit; Baum, Anke

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078735	A1	20001228	WO 2000-EP5547	20000616
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 1999-19928281A 19990621				

DE 19928281	A1	20001228	US 1999-146644PP 19990730
DE 10023085	A1	20011115	DE 2000-10023085A 20000511
BR 2000011834	A	20020312	DE 1999-19928281 19990621
			DE 2000-10023085 20000511
			BR 2000-11834 20000616
			DE 1999-19928281A 19990621
			DE 2000-10023085A 20000511
EP 1194418	A1	20020410	WO 2000-EP5547 W 20000616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			EP 2000-936888 20000616
IE, SI, LT, LV, FI, RO			
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
JP 2003502410	T2	20030121	WO 2000-EP5547 W 20000616
			JP 2001-504901 20000616
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
EE 200100695	A	20030217	WO 2000-EP5547 W 20000616
			EE 2001-695 20000616
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
BG 106189	A	20020830	WO 2000-EP5547 W 20000616
			BG 2001-106189 20011207
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
US 2002169180	A1	20021114	WO 2000-EP5547 W 20000616
			US 2001-16280 20011210
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
NO 2001006185	A	20011218	NO 2001-6185 20011218
			DE 1999-19928281A 19990621
			US 1999-146644PP 19990730
			DE 2000-10023085A 20000511
			WO 2000-EP5547 W 20000616


OS MARPAT 134:71599

IT 314771-10-3P 314771-12-5P 314771-20-5P
 314771-21-6P 314771-26-1P 314771-27-2P
 314771-28-3P 314771-31-8P 314771-32-9P
 314771-33-0P 314771-34-1P 314771-45-4P
 314771-46-5P 314771-47-6P 314771-48-7P
 314771-49-8P 314771-50-1P 314771-51-2P
 314771-52-3P 314771-53-4P 314771-54-5P
 314771-55-6P 314771-56-7P 314771-57-8P
 314771-58-9P 314771-60-3P 314771-61-4P
 314771-62-5P 314771-63-6P 314771-64-7P
 314771-65-8P 314771-67-0P 314771-68-1P
 314771-69-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of aminoquinazolines and aminoquinolines as epidermal growth factor receptor signal transduction inhibitors)


RN 314771-10-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 314771-12-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-piperidiny)- (9CI) (CA INDEX NAME)




RN 314771-20-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-bromophenyl)amino]-7-[(1-methyl-4-piperidiny)methoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 314771-21-6 CAPLUS

CN 2-Butenoic acid, 4-[[4-[(3-bromophenyl)amino]-7-[3-(1-methyl-4-piperidinyl)propoxy]-6-quinazolinyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 314771-26-1 CAPLUS

CN 2,4-Hexadienamide, N-[4-[(3-bromophenyl)amino]-7-[3-(1-methyl-4-piperidinyl)propoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 314771-27-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-bromophenyl)amino]-7-[3-(1-methyl-4-piperidinyl)propoxy]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 314771-28-3 CAPLUS

CN 2-Propenamide, N-[4-[(3-bromophenyl)amino]-7-[3-(1-methyl-4-piperidinyl)propoxy]-6-quinazolinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 314771-31-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 314771-32-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 314771-33-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2,6-dimethyl-4-morpholinyl) - (9CI) (CA INDEX NAME)




RN 314771-34-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-oxido-4-thiomorpholinyl) - (9CI) (CA INDEX NAME)



RN 314771-45-4 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[methyl(1-methyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)



RN 314771-46-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[(2R)-2-(methoxymethyl)-1-pyrrolidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 314771-47-6 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazoliny]-4-[(2S)-2-(methoxymethyl)-1-pyrrolidiny]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 314771-48-7 CAPLUS


CN 2-Butenamide, 4-[bis(2-methoxyethyl)amino]-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 314771-49-8 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[ethyl(2-methoxyethyl)amino]- (9CI) (CA INDEX NAME)






RN 314771-50-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 314771-51-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 314771-52-3 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 314771-53-4 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-(cyclopropylmethyl)-1-piperazinyl]-(9CI) (CA INDEX NAME)




RN 314771-54-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-methyl-1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 314771-55-6 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 314771-56-7 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2R,6S)-2,6-dimethyl-1-piperidiny]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 314771-57-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2,5-dimethyl-1-pyrrolidiny)- (9CI) (CA INDEX NAME)




RN 314771-58-9 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydro-2-furanyl)methoxy]-6-quinazolinyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 314771-60-3 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[4-[(diethylamino)methyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 314771-61-4 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-

6-quinazolinyl]-4-[(cyclopropylmethyl)methylamino] - (9CI) (CA INDEX NAME)




RN 314771-62-5 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxycyclopropyl)methylamino] - (9CI) (CA INDEX NAME)




RN 314771-63-6 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(3-methoxypropyl)methylamino] - (9CI) (CA INDEX NAME)




RN 314771-64-7 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-methoxy-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 314771-65-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(4-hydroxy-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 314771-67-0 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl[(tetrahydro-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 314771-68-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-3-furanyl)amino]-(9CI) (CA INDEX NAME)



RN 314771-69-2 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(2-methoxy-1-methylethyl)methylamino]-(9CI) (CA INDEX NAME)



GI

Patel

<6/302003>



I

AB Title compds. [I; Ra = H, alkyl; Rb = (substituted) Ph, PhCH₂, PhCH₂CH₂; Rc = (substituted) cycloalkoxy, cycloalkylalkoxy; A = (alkyl-substituted) imino; B = CO, SO₂; C = (substituted) allenylene, vinylene, butadienylene, ethynylene; D = (fluorinated) alkylene, carbonylalkylene, sulfonylalkylene, carbonyloxyalkylene, carbonyliminoalkylene, bond, etc.; E = amino, (substituted) alkylamino, dialkylamino, etc.], were prepd. Thus, 6-amino-4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propoxy]quinazoline (prepn. given) in CH₂Cl₂ contg. Et₃N at -10.degree. was treated with acryloyl chloride in THF to give 35% 4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline. The latter inhibited EGF-dependent proliferation of F/L HERC cells with IC₅₀ = <0.35 nM.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2000:628125 CAPLUS

DN 133:207919

TI Preparation of 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases

IN Himmelsbach, Frank; Langkopf, Elke; Jung, Birgit; Metz, Thomas; Solca, Flavio; Blech, Stefan

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051991	A1	20000908	WO 2000-EP1496	20000224
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
DE 19908567	A1	20000831	DE 1999-19908567	19990227

DE 19911366	A1	20000921	DE 1999-19911366	19990315
DE 19928306	A1	20001228	DE 1999-19928306	19990621
DE 19954816	A1	20010517	DE 1999-19954816	19991113
CA 2361174	AA	20000908	CA 2000-2361174	20000224
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
EP 1157011	A1	20011128	WO 2000-EP1496 W	20000224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			EP 2000-910695	20000224
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
BR 2000008524	A	20011218	BR 2000-8524	20000224
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
JP 2002538145	T2	20021112	JP 2000-602218	20000224
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
EE 200100449	A	20021216	EE 2001-449	20000224
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
BG 105765	A	20020329	BG 2001-105765	20010801
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
HR 20010617	A1	20021031	HR 2001-617	20010823
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621
			US 1999-149329PP	19990817
			DE 1999-19954816A	19991113
			WO 2000-EP1496 W	20000224
NO 2001004114	A	20011015	NO 2001-4114	20010824
			DE 1999-19908567A	19990227
			DE 1999-19911366A	19990315
			DE 1999-19928306A	19990621

US 1999-149329PP 19990817
 DE 1999-19954816A 19991113
 WO 2000-EP1496 W 20000224

PATENT FAMILY INFORMATION:

FAN 2000:607393

	PATENT NO.	KIND	DATE
PI	DE 19908567	A1	20000831
	CA 2361174	AA	20000908

	APPLICATION NO.	DATE
	DE 1999-19908567	19990227
	CA 2000-2361174	20000224
	DE 1999-19908567A	19990227
	DE 1999-19911366A	19990315
	DE 1999-19928306A	19990621
	US 1999-149329PP	19990817
	DE 1999-19954816A	19991113
	WO 2000-EP1496 W	20000224
	WO 2000-EP1496	20000224

WO 2000051991 A1 20000908

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 1999-19908567A 19990227
 DE 1999-19911366A 19990315
 DE 1999-19928306A 19990621
 US 1999-149329PP 19990817
 DE 1999-19954816A 19991113
 NZ 2000-513802 20000224
 DE 1999-19908567A 19990227
 DE 1999-19911366A 19990315
 DE 1999-19928306A 19990621
 US 1999-149329PP 19990817
 DE 1999-19954816A 19991113
 EP 2000-910695 20000224

NZ 513802 A 20010928

EP 1157011 A1 20011128

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

DE 1999-19908567A 19990227
 DE 1999-19911366A 19990315
 DE 1999-19928306A 19990621
 US 1999-149329PP 19990817
 DE 1999-19954816A 19991113
 WO 2000-EP1496 W 20000224
 BR 2000-8524 20000224
 DE 1999-19908567A 19990227
 DE 1999-19911366A 19990315
 DE 1999-19928306A 19990621
 US 1999-149329PP 19990817
 DE 1999-19954816A 19991113
 WO 2000-EP1496 W 20000224

BR 2000008524 A 20011218

JP 2002538145 T2 20021112

JP 2000-602218 20000224
 DE 1999-19908567A 19990227
 DE 1999-19911366A 19990315
 DE 1999-19928306A 19990621
 US 1999-149329PP 19990817
 DE 1999-19954816A 19991113

EE 200100449	A	20021216	WO 2000-EP1496 W 20000224 EE 2001-449 20000224 DE 1999-19908567A 19990227 DE 1999-19911366A 19990315 DE 1999-19928306A 19990621 US 1999-149329PP 19990817 DE 1999-19954816A 19991113 WO 2000-EP1496 W 20000224
BG 105765	A	20020329	BG 2001-105765 20010801 DE 1999-19908567A 19990227 DE 1999-19911366A 19990315 DE 1999-19928306A 19990621 US 1999-149329PP 19990817 DE 1999-19954816A 19991113 WO 2000-EP1496 W 20000224
HR 20010617	A1	20021031	HR 2001-617 20010823 DE 1999-19908567A 19990227 DE 1999-19911366A 19990315 DE 1999-19928306A 19990621 US 1999-149329PP 19990817 DE 1999-19954816A 19991113 WO 2000-EP1496 W 20000224
NO 2001004114	A	20011015	NO 2001-4114 20010824 DE 1999-19908567A 19990227 DE 1999-19911366A 19990315 DE 1999-19928306A 19990621 US 1999-149329PP 19990817 DE 1999-19954816A 19991113 WO 2000-EP1496 W 20000224


OS MARPAT 133:207919

IT 290302-11-3P 290302-19-1P 290302-25-9P
290302-39-5P 290302-47-5P 290302-98-6P
290303-04-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)


RN 290302-11-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-19-1 CAPLUS

CN .beta.-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-25-9 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290302-39-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(2-


cyclopropylethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
(9CI) (CA INDEX NAME)



RN 290302-47-5 CAPLUS


CN L-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290302-98-6 CAPLUS

CN Glycine, N-[2-(acetylthio)ethyl]-N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290303-04-7 CAPLUS

CN Glycine, N-[2-(acetyloxy)ethyl]-N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 290303-47-8P 290303-74-1P 290303-84-3P


290303-96-7P 290304-01-7P 290304-02-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)


RN 290303-47-8 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 290303-74-1 CAPLUS

CN 2-Butenoic acid, 4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 290303-84-3 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-[2-[(methylsulfonyl)oxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290303-96-7 CAPLUS


CN 2-Butenoic acid, 4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-

(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 290304-01-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 290304-02-8 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 1-(1,1-dimethylethyl) 3-ethyl ester (9CI) (CA INDEX NAME)




IT 290303-13-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)

(prepn. of aminoquinazoline and aminoquinoline derivs. having an
 inhibitory effect on signal transduction mediated by tyrosine kinases
 useful for treating tumoral diseases, lung and respiratory tract
 diseases)

RN 290303-13-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



IT 290301-79-0P 290301-80-3P 290301-81-4P
 290301-82-5P 290301-85-8P 290302-09-9P
 290302-15-7P 290302-21-5P 290302-23-7P
 290302-27-1P 290302-29-3P 290302-35-1P
 290302-37-3P 290302-43-1P 290302-45-3P
 290302-49-7P 290302-51-1P 290302-53-3P
 290302-55-5P 290302-57-7P 290302-59-9P
 290302-61-3P 290302-63-5P 290302-65-7P
 290302-67-9P 290302-71-5P 290302-73-7P
 290302-81-7P 290302-83-9P 290302-89-5P
 290302-91-9P 290302-93-1P 290302-94-2P
 290303-00-3P 290303-02-5P 290303-03-6P


290303-05-8P 290303-06-9P 290303-07-0P
 290303-08-1P 290303-09-2P 290303-10-5P
 290303-11-6P 290303-12-7P 290303-14-9P
 290303-15-0P 290303-16-1P 290303-17-2P
 290303-18-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoquinazoline and aminoquinoline derivs. having an inhibitory effect on signal transduction mediated by tyrosine kinases useful for treating tumoral diseases, lung and respiratory tract diseases)


RN 290301-79-0 CAPLUS

CN Glycine, N-[7-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4,7-dioxo-5-heptenyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 290301-80-3 CAPLUS

CN Glycine, N-[6-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-3,6-dioxo-4-hexenyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 290301-81-4 CAPLUS


CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,4-dioxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290301-82-5 CAPLUS


CN L-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,4-dioxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290301-85-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-bromophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, [[(1,1-dimethylethoxy)carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 290302-09-9 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-15-7 CAPLUS


CN Propanedioic acid, [[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]methylamino]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 290302-21-5 CAPLUS


CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester (9CI) (CA INDEX NAME)

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 290302-23-7 CAPLUS


CN .beta.-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(3-ethoxy-3-oxopropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-27-1 CAPLUS


CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)






RN 290302-29-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclohexylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-35-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclobutylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-37-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-43-1 CAPLUS

CN Glycine, N-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxy-2-methylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-45-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[4-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 290302-49-7 CAPLUS

CN Glycine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 290302-51-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5,5-dimethyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290302-53-3 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(5-methyl-2-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290302-55-5 CAPLUS

CN D-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 290302-57-7 CAPLUS

CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, diethyl ester, (2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 290302-59-9 CAPLUS

CN 2,6-Piperidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 290302-61-3 CAPLUS

CN 2,6-Piperidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 290302-63-5 CAPLUS

CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 290302-65-7 CAPLUS


CN 2,5-Pyrrolidinedicarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, dimethyl ester, (2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 290302-67-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1-methyl-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-71-5 CAPLUS

CN Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 290302-73-7 CAPLUS

CN L-Proline, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 290302-81-7 CAPLUS

CN 2-Piperidineacetic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290302-83-9 CAPLUS

CN Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-89-5 CAPLUS

CN D-Alanine, N-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-N-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 290302-91-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]hexahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 290302-93-1 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-2-oxo-3-furanyl)amino]-(9CI) (CA INDEX NAME)




RN 290302-94-2 CAPLUS

CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[methyl(tetrahydro-5-oxo-3-furanyl)amino]-(9CI) (CA INDEX NAME)




RN 290303-00-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-(9CI) (CA INDEX NAME)



RN 290303-02-5 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-(2,2-dimethyl-6-oxo-4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 290303-03-6 CAPLUS


CN 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]-4-[(3R)-3-methyl-2-oxo-4-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 290303-05-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 290303-06-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 290303-07-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, 2,3-dihydro-1H-inden-5-yl ester (9CI) (CA INDEX NAME)




RN 290303-08-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)




RN 290303-09-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 290303-10-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, hexyl ester (9CI) (CA INDEX NAME)




RN 290303-11-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-3-(ethoxycarbonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-12-7 CAPLUS

CN 1-Piperazinebutanoic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-14-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-15-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-4-(methylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-16-1 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 290303-17-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-1,1-dimethyl-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 290303-18-3 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-acetyl-1-[4-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopropylmethoxy)-6-quinazolinyl]amino]-4-oxo-2-butenyl]-, ethyl ester (9CI) (CA INDEX NAME)




GI

Patel

<6/302003>



I



II

AB Title compds. [I; R1 = H, C1-C4-alkyl; R2 = (un)substituted Ph, benzyl, 1-phenylethyl; R3, R4 independently = H, F, Cl, CH3O, CH3OCH2, (CH3)2NCH2, (CH3CH2)2NCH2, pyrrolidino, piperidino, morpholino; X = C(CN), N; A = O, NH, (C1-C4)-alkylN; B = CO, SO2; C = 1,3-allenylene, 1,1-vinylene, 1,2-vinylene, 1,3-butadien-1,4-ylene, with CH3, CF3 substitution; D = alkylene, CO-alkylene, SO2-alkylene; CO, SO2; E = HOCO(CH2)nNR5, (HO)2P(:O)(CH2)nNR5; n = 1-6; R5 = H, alkyl], tautomers, stereoisomers, and physiol. acceptable salts are prepd. and having valuable pharmacol. properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases. Title compds. are useful for treating tumoral diseases, diseases of the lungs and respiratory tract. Thus, the title compd. II was prepd. and tested by Cell Titer 96TM Aq. Nonradioactive Cell Proliferation Assay.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d cost

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34	0.83
NETWORK CHARGES	0.06	0.18
SEARCH CHARGES	0.00	147.75
DISPLAY CHARGES	47.49	47.49
	-----	-----
CAPLUS FEE (5%)	47.89	196.25
	2.39	2.39
	-----	-----
FULL ESTIMATED COST	50.28	198.64

Patel

<6/302003>

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

-4.56

-4.56

IN FILE 'CAPLUS' AT 13:04:16 ON 30 JUN 2003